Navigation Links
Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
Date:11/13/2007

MOORESVILLE, N.C., Nov. 13 /PRNewswire-FirstCall/ -- Anpath Group, Inc. (OTC Bulletin Board: ANPG), reported today that its wholly-owned subsidiary, EnviroSystems, Inc. (ESI) announced the selection of its disinfectant, EnviroTru(TM) for use by the Washington Metropolitan Area Transit Authority (Metro).

EnviroTru(TM) is a multi-purpose disinfectant and deodorizing cleaner effective against numerous organisms, and also meets EPA requirements for Toxicity Category IV (no harmful dermal, ocular, inhalation or ingestion effects). ESI reported that Metro recently placed an initial order for more than 600 gallons of the disinfectant.

"It is especially gratifying for our product/technology to be chosen by the transit system serving our Nation's Capital", stated ESI President and CEO, J. Lloyd Breedlove. Mr. Breedlove continued, "EnviroTru(TM) is ideally suited for use in a transit system environment. As a result of its biocidal efficacy combined with its favorable materials compatibility and environmental profile EnviroTru(TM) is a natural choice for heavy traffic areas".

Metro is the tri-jurisdictional government agency authorized by Congress to operate the transit service in the Washington, DC metropolitan area, including the Metrorail and Metrobus; totaling more than 11,000 rail cars, buses and special means transport vehicles. Metro is also part of the public- private partnership that operates the DC Circulator bus system. Polly Hanson, Assistant General Manager of Safety, Security and Emergency Management with Metro stated, "We are pleased to have identified and selected a product with the characteristics of EnviroTru(TM). It is important that we make every effort to protect our customers and employees against the spread of infectious diseases without exposing them to harmful chemicals, while also taking into account our equipment and the environment in general."

ESI stated that in addition to daily application of EnviroTru(TM) on high hand contact areas such as door handles, hand rails, fare card machine buttons, etc., in the event of a pandemic flu or other infectious disease outbreak Metro is prepared to use EnviroTru(TM) with the Foster-Miller, Inc. Electrostatic Charged Aerosol Decontamination System (ECADS) (http://www.fostermiller.com/ecadsproduct.htm) to spray rail cars, buses and other vehicles daily. ESI worked with Foster-Miller, Inc. to validate the use of its disinfectant with ECADS.

According to Foster-Miller, Inc. representative, Rick Lusignea, "Metro purchased 17 high efficiency air assisted ECADS sprayers from Foster-Miller to dispense EnviroTru(TM)". Mr. Lusignea explained, "The ECAD decontamination and remediation system disperses fine electrically charged droplets of decontaminant into the air. Because of the static charge imparted to aerosol particles, ECADS provides a much higher amount of disinfectant on surfaces than conventional air assisted spray systems, approximately 60% of the total disinfectant dispensed on the surface for the ECADS sprayer, versus less than 15% for conventional sprayers. We think the combination of our ECADS devices and the ESI disinfectant formulation is an extremely strong weapon against disease for Metro."

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.


'/>"/>
SOURCE Anpath Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):